Cargando…

Preexisting Antibodies to an F(ab′)(2) Antibody Therapeutic and Novel Method for Immunogenicity Assessment

Anti-therapeutic antibodies (ATAs) may impact drug exposure and activity and induce immune complex mediated toxicity; therefore the accurate measurement of ATA is important for the analysis of drug safety and efficacy. Preexisting ATAs to the hinge region of anti-Delta like ligand 4 (anti-DLL4) F(ab...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ruppel, Jane, Brady, Ann, Elliott, Rebecca, Leddy, Cecilia, Palencia, Marco, Coleman, Daniel, Couch, Jessica A., Wakshull, Eric
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4927981/ https://www.ncbi.nlm.nih.gov/pubmed/27413757 http://dx.doi.org/10.1155/2016/2921758

Ejemplares similares

Design of antibody variable fragments with reduced reactivity to preexisting anti-drug antibodies
por: Johansson, Maria U., et al.
Publicado: (2023)

Immunogenicity of immunomodulatory, antibody-based, oncology therapeutics
por: Davda, Jasmine, et al.
Publicado: (2019)

Cross-reactive and pre-existing antibodies to therapeutic antibodies—Effects on treatment and immunogenicity
por: van Schie, Karin A, et al.
Publicado: (2015)

Prediction of immunogenicity for humanized and full human therapeutic antibodies
por: Liang, Shide, et al.
Publicado: (2020)

The immunogenicity of chimeric antibodies
Publicado: (1989)

P3 mAb: An Immunogenic Anti-NeuGcGM3 Antibody with Unusual Immunoregulatory Properties
por: Martínez, Darel, et al.
Publicado: (2012)

AbLang: an antibody language model for completing antibody sequences
por: Olsen, Tobias H, et al.
Publicado: (2022)

The Therapeutic Value of Monoclonal Antibodies Directed Against Immunogenic Tumor Glycoproteins
por: Arlen, Myron, et al.
Publicado: (2010)

Immunogenicity of Bioproducts: Cellular Models to Evaluate the Impact of Therapeutic Antibody Aggregates
por: Nabhan, Myriam, et al.
Publicado: (2020)

Immunogenicity Risk Assessment of Spontaneously Occurring Therapeutic Monoclonal Antibody Aggregates
por: Swanson, Michael D., et al.
Publicado: (2022)

The immunogenicity of human-origin therapeutic antibodies are associated with V gene usage
por: Hu, Zicheng, et al.
Publicado: (2023)

Oracle or false prophet? Can we predict AAV efficacy based on preexisting antibody titers?
por: Anguela, Xavier M., et al.
Publicado: (2019)

Testing preexisting antibodies prior to AAV gene transfer therapy: rationale, lessons and future considerations
por: Mendell, Jerry R., et al.
Publicado: (2022)

BMFPs, a versatile therapeutic tool for redirecting a preexisting Epstein-Barr virus antibody response toward defined target cells
por: Gamain, Benoît, et al.
Publicado: (2022)

Conjugation of R-Phycoerythrin to a Polyclonal Antibody and F (ab')2 Fragment of a Polyclonal Antibody by Two Different Methods
por: Mahmoudian, Jafar, et al.
Publicado: (2010)

Introduction of the YTE mutation into the non-immunogenic HIV bnAb PGT121 induces anti-drug antibodies in macaques
por: Rosenberg, Yvonne J., et al.
Publicado: (2019)

Immunogenicity assessment of bispecific antibody-based immunotherapy in oncology
por: Zhou, Yanchen, et al.
Publicado: (2022)

Antibody markup language (AbML) — a notation language for antibody-based drug formats and software for creating and rendering AbML (abYdraw)
por: Sweet-Jones, James, et al.
Publicado: (2022)

Pharmacokinetics, immunogenicity and bioactivity of the therapeutic antibody catumaxomab intraperitoneally administered to cancer patients
por: Ruf, Peter, et al.
Publicado: (2010)

The effect of immunomodulators on the immunogenicity of TNF-blocking therapeutic monoclonal antibodies: a review
por: Krieckaert, Charlotte Louise Maria, et al.
Publicado: (2010)

Production and purification of polyclonal antibody against F(ab')2 fragment of human immunoglobulin G
por: Nasiri, Hadi, et al.
Publicado: (2017)

Immunogenicity of Innovative and Biosimilar Monoclonal Antibodies
por: Doevendans, Erik, et al.
Publicado: (2019)

AbDiver: a tool to explore the natural antibody landscape to aid therapeutic design
por: Młokosiewicz, Jakub, et al.
Publicado: (2022)

A majority of uninfected adults show preexisting antibody reactivity against SARS-CoV-2
por: Majdoubi, Abdelilah, et al.
Publicado: (2021)

Vaccine comprising anti-idiotype antibody conjugate; induces production of neutralizing antibody (human monoclonal antibody, chimeric antibody or FAb, F(Ab′) 2 or Fv fragment) against HIV virus-1
Publicado: (1992)

The impact of immunogenicity on therapeutic antibody pharmacokinetics: A preclinical evaluation of the effect of immune complex formation and antibody effector function on clearance
por: Opolka-Hoffmann, Eugenia, et al.
Publicado: (2021)

Galactosylated streptavidin for improved clearance of biotinylated intact and F(ab')2 fragments of an anti-tumour antibody.
por: Marshall, D., et al.
Publicado: (1995)

High efficiency reduction capability for the formation of Fab׳ antibody fragments from F(ab)(2) units
por: Crivianu-Gaita, Victor, et al.
Publicado: (2015)

cAb-Rep: A Database of Curated Antibody Repertoires for Exploring Antibody Diversity and Predicting Antibody Prevalence
por: Guo, Yicheng, et al.
Publicado: (2019)

AB-Amy: machine learning aided amyloidogenic risk prediction of therapeutic antibody light chains
por: Zhou, Yuwei, et al.
Publicado: (2023)

AbDb: antibody structure database—a database of PDB-derived antibody structures
por: Ferdous, Saba, et al.
Publicado: (2018)

Antibody Binding Epitope Mapping (AbMap) of Hundred Antibodies in a Single Run
por: Qi, Huan, et al.
Publicado: (2021)

Multiple mechanisms mediate enhanced immunity generated by mAb-inactivated F. tularensis immunogen
por: Iglesias, Bibiana V., et al.
Publicado: (2012)

To bnAb or Not to bnAb: Defining Broadly Neutralising Antibodies Against HIV-1
por: Griffith, Sarah A., et al.
Publicado: (2021)

Enhanced antigen immunogenicity induced by bispecific antibodies
Publicado: (1990)

Ab locks for improving the selectivity and safety of antibody drugs
por: Lin, Wen-Wei, et al.
Publicado: (2020)

Predicting the F(ab)-mediated effect of monoclonal antibodies in vivo by combining cell-level kinetic and pharmacokinetic modelling
por: Krippendorff, Ben-Fillippo, et al.
Publicado: (2012)

Preexisting Japanese Encephalitis Virus Neutralizing Antibodies and Increased Symptomatic Dengue Illness in a School-Based Cohort in Thailand
por: Anderson, Kathryn B., et al.
Publicado: (2011)

Clinical enrollment assay to detect preexisting neutralizing antibodies to AAV6 with demonstrated transgene expression in gene therapy trials
por: Cao, Liching, et al.
Publicado: (2022)

Preexisting immunity restricts mucosal antibody recognition of SARS-CoV-2 and Fc profiles during breakthrough infections
por: Selva, Kevin J., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_4jetu05060iqq78jra9nre93vj